Pulmonary Adverse Events in Patients Receiving Low ‐Dose Methotrexate in the Randomized, Double‐Blind, Placebo‐Controlled Cardiovascular Inflammation Reduction Trial
ConclusionIn this large placebo ‐controlled trial, pulmonary AEs, including possible pneumonitis, were uncommon but were more likely to occur in those randomized to receive low‐dose MTX. White race, older age, male sex, and insulin use were associated with an increased risk of pulmonary AEs in those receiving low‐dose MTX.
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Jeffrey A. Sparks,
Paul F. Dellaripa,
Robert J. Glynn,
Nina P. Paynter,
Chang Xu,
Paul M. Ridker,
Daniel H. Solomon Tags: Brief Report Source Type: research
More News: Arthritis | Cardiology | Cardiovascular | Diabetes | Endocrinology | Eyes | Heart | Insulin | Metabolic Syndrome | Methotrexate | Rheumatology